J A Sloan

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. pmc A brief Patient-Reported Outcomes Quality of Life (PROQOL) instrument to improve patient care
    Jennifer L Ridgeway
    Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United States of America
    PLoS Med 10:e1001548. 2013
  2. pmc Relationship between deficits in overall quality of life and non-small-cell lung cancer survival
    Jeff A Sloan
    Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 30:1498-504. 2012
  3. pmc Genetic variations and patient-reported quality of life among patients with lung cancer
    Jeff A Sloan
    Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 30:1699-704. 2012
  4. pmc Responsiveness and minimal important differences for patient reported outcomes
    Dennis A Revicki
    Center for Health Outcomes Research, United BioSource Corporation, 7101 Wisconsin Ave, Suite 600, Bethesda, MD 20814, USA
    Health Qual Life Outcomes 4:70. 2006
  5. pmc Development and preliminary psychometric properties of a well-being index for medical students
    Liselotte N Dyrbye
    Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    BMC Med Educ 10:8. 2010
  6. pmc Towards the prevention of acute lung injury: a population based cohort study protocol
    Sweta J Thakur
    Multidisciplinary Epidemiology and Translational Research in Intensive Care, Division of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    BMC Emerg Med 10:8. 2010
  7. ncbi request reprint The clinical significance of quality of life assessments in oncology: a summary for clinicians
    Jeff A Sloan
    Department of Health Sciences Research, Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Support Care Cancer 14:988-98. 2006
  8. ncbi request reprint Limited sampling models for CPT-11, SN-38, and SN-38 glucuronide
    J A Sloan
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Cancer Chemother Pharmacol 48:241-9. 2001
  9. ncbi request reprint Issues for statisticians in conducting analyses and translating results for quality of life end points in clinical trials
    J A Sloan
    Department of Health Sciences Research, Mayo Clinic Cancer Center, Rochester, Minnesota 55905, USA
    J Biopharm Stat 14:73-96. 2004
  10. ncbi request reprint A quality-adjusted reanalysis of a Phase III trial comparing once-daily thoracic radiation vs. twice-daily thoracic radiation in patients with limited-stage small-cell lung cancer(1)
    Jeff A Sloan
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Int J Radiat Oncol Biol Phys 52:371-81. 2002

Detail Information

Publications119 found, 100 shown here

  1. pmc A brief Patient-Reported Outcomes Quality of Life (PROQOL) instrument to improve patient care
    Jennifer L Ridgeway
    Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United States of America
    PLoS Med 10:e1001548. 2013
    ..Please see later in the article for the Editors' Summary. ..
  2. pmc Relationship between deficits in overall quality of life and non-small-cell lung cancer survival
    Jeff A Sloan
    Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 30:1498-504. 2012
    ..This study evaluated the prognostic value of QOL assessments with regard to OS in a large cohort of patients with lung cancer...
  3. pmc Genetic variations and patient-reported quality of life among patients with lung cancer
    Jeff A Sloan
    Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 30:1699-704. 2012
    ..We report an analysis exploring relationships among baseline QOL assessments and candidate genetic variations in a large cohort of patients with lung cancer...
  4. pmc Responsiveness and minimal important differences for patient reported outcomes
    Dennis A Revicki
    Center for Health Outcomes Research, United BioSource Corporation, 7101 Wisconsin Ave, Suite 600, Bethesda, MD 20814, USA
    Health Qual Life Outcomes 4:70. 2006
    ..Responsiveness and MID must be demonstrated and documented for the particular study population, and these measurement characteristics are needed for PRO labeling and promotional claims...
  5. pmc Development and preliminary psychometric properties of a well-being index for medical students
    Liselotte N Dyrbye
    Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    BMC Med Educ 10:8. 2010
    ....
  6. pmc Towards the prevention of acute lung injury: a population based cohort study protocol
    Sweta J Thakur
    Multidisciplinary Epidemiology and Translational Research in Intensive Care, Division of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    BMC Emerg Med 10:8. 2010
    ..Olmsted County, MN, geographically isolated from other urban areas offers the opportunity to study clinical pathogenesis of ALI in a search for potential prevention targets...
  7. ncbi request reprint The clinical significance of quality of life assessments in oncology: a summary for clinicians
    Jeff A Sloan
    Department of Health Sciences Research, Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Support Care Cancer 14:988-98. 2006
    ....
  8. ncbi request reprint Limited sampling models for CPT-11, SN-38, and SN-38 glucuronide
    J A Sloan
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Cancer Chemother Pharmacol 48:241-9. 2001
    ..We developed limited sampling models (LSMs) for predicting the area under the curve (AUC) of irinotecan (CPT-11) and its metabolites SN-38 and SN-38 glucuronide (SN-38G)...
  9. ncbi request reprint Issues for statisticians in conducting analyses and translating results for quality of life end points in clinical trials
    J A Sloan
    Department of Health Sciences Research, Mayo Clinic Cancer Center, Rochester, Minnesota 55905, USA
    J Biopharm Stat 14:73-96. 2004
    ..We populate the paper with concrete examples of how QOL data need not be treated any different, in terms of statistical analysis, than tumor response or other clinical end points...
  10. ncbi request reprint A quality-adjusted reanalysis of a Phase III trial comparing once-daily thoracic radiation vs. twice-daily thoracic radiation in patients with limited-stage small-cell lung cancer(1)
    Jeff A Sloan
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Int J Radiat Oncol Biol Phys 52:371-81. 2002
    ....
  11. doi request reprint Metrics to assess quality of life after management of early-stage lung cancer
    Jeff A Sloan
    Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA
    Cancer J 17:63-7. 2011
    ..The primary conclusion from this work is that scientifically sound investigations into the QOL of early-stage lung cancer patients are feasible and encouraged so that the care of these patients can be optimized...
  12. ncbi request reprint Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer
    Jeff A Sloan
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 20:1491-8. 2002
    ..After these findings, an additional meta-analysis of the toxicity profiles on five NCCTG colorectal cancer treatment trials was undertaken...
  13. ncbi request reprint A simple stratification factor prognostic for survival in advanced cancer: the good/bad/uncertain index
    J A Sloan
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 19:3539-46. 2001
    ..The objective was to produce a simple, practical, stratification factor for phase III oncology clinical trials involving patients with advanced malignant disease...
  14. ncbi request reprint A new graphic for quality adjusted life years (Q-TWiST) survival analysis: the Q-TWiST plot
    Jeff A Sloan
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Qual Life Res 11:37-45. 2002
    ..We explore alternative options to customize the graphic representation for other data sets drawn from several NCCTG clinical trials...
  15. ncbi request reprint Patients with reconstruction of craniofacial or intraoral defects: development of instruments to measure quality of life
    J A Sloan
    Mayo Medical School, Rochester, Minnesota, USA
    Int J Oral Maxillofac Implants 16:225-45. 2001
    ..The instruments were used with equal success both in face-to-face interviews and via mail...
  16. ncbi request reprint The Mayo Clinic manuscript series relative to the discussion, dissemination, and operationalization of the Food and Drug Administration guidance on patient-reported outcomes
    Jeff A Sloan
    Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA
    Value Health 10:S59-63. 2007
    ..This is vitally important because after all, at the heart of all healthcare endeavors is the patient...
  17. ncbi request reprint Assessing the minimally clinically significant difference: scientific considerations, challenges and solutions
    Jeff A Sloan
    Mayo Clinic Rochester, Cancer Center Statistics, 200 1st St SW, Rochester, Minnesota 55905, USA
    COPD 2:57-62. 2005
    ..4. A process of MCID estimation involving all approaches to produce a potential range with sensitivity analyses is the optimal solution to producing an MCID based on the most complete knowledge possible...
  18. ncbi request reprint Analysis and interpretation of results based on patient-reported outcomes
    Jeff A Sloan
    Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA
    Value Health 10:S106-15. 2007
    ..g.,missing data, multiplicity, null results etc.). The manuscript provides key literature for existing resources and proposes new guidelines...
  19. ncbi request reprint Integrating patient-reported outcomes into cancer symptom management clinical trials supported by the National Cancer Institute-sponsored clinical trials networks
    Jeff A Sloan
    Department of Health Sciences Research, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 25:5070-7. 2007
    ..There remains a need for more research in several methodologic aspects of design, analysis, and interpretation of symptom management trials...
  20. ncbi request reprint Sex differences in fluorouracil-induced stomatitis
    J A Sloan
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 18:412-20. 2000
    ....
  21. ncbi request reprint Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity
    A A Adjei
    Department of Oncology, Mayo Clinic and Foundation, Rochester, MN, USA
    J Clin Oncol 18:1116-23. 2000
    ....
  22. ncbi request reprint Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors
    A A Adjei
    Department of Oncology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    J Clin Oncol 18:1748-57. 2000
    ..Multitargeted antifolate (MTA) is an investigational agent that, like gemcitabine, exhibits broad activity in solid tumors. A phase I trial of MTA and gemcitabine was undertaken, based on the demonstration of preclinical cytotoxic synergy...
  23. ncbi request reprint Quality of life in 650 lung cancer survivors 6 months to 4 years after diagnosis
    Adam Svobodnik
    Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 79:1024-30. 2004
    ..To present the results of a quality-of-life (QOL) assessment performed with the current version of the Lung Cancer Symptom Scale (LCSS) questionnaire in a large single-institutional data set of 650 patients with lung cancer...
  24. ncbi request reprint Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors
    C L Loprinzi
    Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 16:2377-81. 1998
    ..Anecdotal information suggested a low dose of a relatively new antidepressant, venlafaxine, could abrogate this clinical problem...
  25. ncbi request reprint Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566
    C Erlichman
    Mayo Clinic Cancer Center, Rochester, Minnesota, USA
    Ann Oncol 12:389-95. 2001
    ..We undertook a phase I study of BAY 12-9566, an inhibitor of MMP-2, MMP-9, and MMP-3, in patients with solid tumors to determine its safety, pharmacokinetics, and effects on potential surrogate markers of biologic activity...
  26. ncbi request reprint Phase III double-blind study of glutamine versus placebo for the prevention of acute diarrhea in patients receiving pelvic radiation therapy
    Timothy F Kozelsky
    Mayo Clinic, 200 First St, SW, Rochester, MN 55905, USA
    J Clin Oncol 21:1669-74. 2003
    ....
  27. ncbi request reprint A phase I and pharmacokinetic study of the selective, non-peptidic inhibitor of matrix metalloproteinase BAY 12-9566 in combination with etoposide and carboplatin
    Julian R Molina
    Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Anticancer Drugs 16:997-1002. 2005
    ..However, the combination of BAY, VP-16 and CDBCA produces significant hematologic toxicity. Findings from this study may help to direct further studies with other inhibitors of MMPs...
  28. ncbi request reprint Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial
    C L Loprinzi
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Lancet 356:2059-63. 2000
    ..We undertook a double-blind, placebo-controlled, randomised trial to assess the efficacy of venlafaxine in women with a history of breast cancer or reluctance to take hormonal treatment because of fear of breast cancer...
  29. ncbi request reprint Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia
    C L Loprinzi
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 17:3299-306. 1999
    ..The current trial was developed to compare and contrast a progestational agent, a corticosteroid, and an anabolic corticosteroid for the treatment of cancer anorexia/cachexia...
  30. ncbi request reprint Lack of effect of coumarin in women with lymphedema after treatment for breast cancer
    C L Loprinzi
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    N Engl J Med 340:346-50. 1999
    ..Coumarin has been reported to be effective for the treatment of women with lymphedema; we undertook a study in which we attempted to replicate those findings...
  31. ncbi request reprint Burnout and suicidal ideation among U.S. medical students
    Liselotte N Dyrbye
    Mayo Clinic, Rochester, Minnesota, USA
    Ann Intern Med 149:334-41. 2008
    ..Little is known about the prevalence of suicidal ideation among U.S. medical students or how it relates to burnout...
  32. ncbi request reprint Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy
    Julie E Hammack
    Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Pain 98:195-203. 2002
    ..Cross-validation sensitivity analysis of results support the conclusion that nortriptyline provides modest improvement at best over placebo in terms of chemotherapy-related neuropathy...
  33. ncbi request reprint Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1
    Barbara A Pockaj
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 24:2836-41. 2006
    ..Hot flashes can cause significant morbidity in postmenopausal women undergoing or finished with breast cancer treatment. Black cohosh has been used to treat hot flashes, but definitive clinical data about efficacy have been equivocal...
  34. ncbi request reprint Levetiracetam for the treatment of hot flashes: a phase II study
    Susan Thompson
    Division of Medical Oncology, Mayo Clinic College of Medicine, 200 First Street S W, Rochester, MN 55905, USA
    Support Care Cancer 16:75-82. 2008
    ..The objectives of this pilot trial were to assess the potential efficacy and safety of levetiracetam for the treatment of hot flashes, a major cause of morbidity among breast cancer survivors...
  35. doi request reprint Overall survival and self-reported fatigue in patients with esophageal cancer
    M C Stauder
    Department of Radiation Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Support Care Cancer 21:511-9. 2013
    ..A prospective cohort study was conducted to analyze whether self-reported fatigue predicts overall survival in patients with esophageal cancer...
  36. ncbi request reprint A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin
    R M Goldberg
    Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Ann Oncol 13:1674-80. 2002
    ....
  37. ncbi request reprint A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity
    A A Adjei
    Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 60:1871-7. 2000
    ..i.d.) but also provides the first evidence of successful inhibition of FT in the clinical setting and the first hint of clinical activity for this class of agents...
  38. pmc Complementary and alternative medicine use among long-term lymphoma survivors: a pilot study
    Thomas M Habermann
    Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 84:795-8. 2009
    ..The use of potential agents of risk by the survivors and the lack of access to potentially beneficial modalities highlights the need for further study of CAM in this population...
  39. pmc A pessimistic explanatory style is prognostic for poor lung cancer survival
    Paul Novotny
    Cancer Center Statistics, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    J Thorac Oncol 5:326-32. 2010
    ..Having a pessimistic outlook has been related to negative health behaviors and higher mortality. However, the construct has not been well explored in cancer populations...
  40. ncbi request reprint A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors
    Grace K Dy
    Department of Medicine, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Cancer Chemother Pharmacol 55:522-30. 2005
    ..The present study was undertaken to evaluate the efficacy, toxicity, and pharmacokinetics of gemcitabine and pemetrexed when pemetrexed is administered immediately after gemcitabine...
  41. ncbi request reprint A prospective study of quality of life in adults with newly diagnosed high-grade gliomas: the impact of the extent of resection on quality of life and survival
    Paul D Brown
    Division of Radiation Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Neurosurgery 57:495-504; discussion 495-504. 2005
    ..To describe the quality of life (QOL) over time for adults with newly diagnosed high-grade gliomas and to examine the relationship between QOL and outcome data collected in three prospective cooperative group clinical trials...
  42. ncbi request reprint Methodologic lessons learned from hot flash studies
    J A Sloan
    Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 19:4280-90. 2001
    ..CONCLUSION: Given the data gained from these experiences, we can plan and carry out more efficient trials to identify efficacious agents for the reduction of hot flash activity...
  43. ncbi request reprint Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer
    C L Loprinzi
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 15:969-73. 1997
    ..The present trial was developed to evaluate the nonhormonal vaginal lubricating preparation, Replens, for alleviating these symptoms...
  44. ncbi request reprint Tamoxifen-induced hot flashes
    C L Loprinzi
    Mayo Clinic, Mayo Foundation, Rochester, MN, USA
    Clin Breast Cancer 1:52-6. 2000
    ....
  45. ncbi request reprint On appetite and its loss
    Aminah Jatoi
    Division of Medical Oncology and Department of Biostatistics, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 21:79s-81s. 2003
  46. ncbi request reprint Complementary and alternative medicine use by patients enrolled onto phase I clinical trials
    Grace K Dy
    Division of Medical Oncology, Department of Medicine, Mayo Foundation and Mayo Clinic College of Medicine, Rochester, MN, USA
    J Clin Oncol 22:4810-5. 2004
    ..To describe the prevalence, clinical characteristics, and pattern of use of complementary and alternative medicine (CAM) in patients enrolled onto phase I trials...
  47. doi request reprint North Central Cancer Treatment Group--achievements and perspectives
    Axel Grothey
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Semin Oncol 35:530-44. 2008
    ....
  48. ncbi request reprint Lung cancer screening with CT: Mayo Clinic experience
    Stephen J Swensen
    Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Radiology 226:756-61. 2003
    ..To evaluate a large cohort of patients at high risk for lung cancer by using screening with low-dose spiral computed tomography (CT) of the chest...
  49. ncbi request reprint Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas
    E Galanis
    Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA
    Gene Ther 12:437-45. 2005
    ..There was evidence of antitumor activity in one out of six patients. Further investigation of this approach in patients with recurrent sarcomas is warranted...
  50. ncbi request reprint A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma
    A Dispenzieri
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leukemia 19:118-25. 2005
    ..Overall response rate was 94% including seven very good partial responses and five complete responses. Addition of 153Sm EDTMP to melphalan conditioning appears to be safe, well-tolerated and worthy of further study...
  51. pmc Motivational readiness for physical activity and quality of life in long-term lung cancer survivors
    Matthew M Clark
    Department of Psychiatry and Psychology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, United States
    Lung Cancer 61:117-22. 2008
    ..Physical activity level may have important QOL and symptom management benefits for long-term lung cancer survivors...
  52. ncbi request reprint Measuring spiritual quality of life in patients with cancer
    Mary E Johnson
    Department of Chaplain Services, Mayo Clinic, Rochester, MN 55905, USA
    J Support Oncol 5:437-42. 2007
    ....
  53. pmc How do distress and well-being relate to medical student empathy? A multicenter study
    Matthew R Thomas
    Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Gen Intern Med 22:177-83. 2007
    ....
  54. ncbi request reprint Meeting on the FDA draft guidance on patient-reported outcomes
    Amylou C Dueck
    Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA
    Value Health 10:S64-5. 2007
  55. doi request reprint A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021
    Scott H Okuno
    Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer 112:1772-9. 2008
    ....
  56. pmc Validation of single-item linear analog scale assessment of quality of life in neuro-oncology patients
    Dona E C Locke
    Department of Psychiatry and Psychology, Mayo Clinic, Scottsdale, Arizona 85259, USA
    J Pain Symptom Manage 34:628-38. 2007
    ..The data suggest that the single-item LASA scales are valid for assessing QOL of cancer patients and are an appropriate alternative when a shorter instrument is warranted...
  57. doi request reprint Mayo Clinic and North Central Cancer Treatment Group hot flash studies: a 20-year experience
    Charles L Loprinzi
    Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Menopause 15:655-60. 2008
    ..This project was designed to provide an overview of hot flash studies conducted over the past two decades at the Mayo Clinic and in the North Central Cancer Treatment Group...
  58. doi request reprint Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3
    Ravi D Rao
    Department of Medical Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer 112:2802-8. 2008
    ..Based on such data, a multicenter double-blind, placebo-controlled, randomized trial was conducted to evaluate the effect of lamotrigine on pain and other neuropathic symptoms due to chemotherapy-induced peripheral neuropathy (CIPN)...
  59. doi request reprint Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB)
    Aminah Jatoi
    Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer 113:847-53. 2008
    ..Epidermal growth factor receptor (EGFR) inhibitors are effective cancer therapies, but they are reported to cause a rash in >50% of patients. In the current study, the authors examined the use of tetracycline for rash prevention...
  60. doi request reprint Burnout and serious thoughts of dropping out of medical school: a multi-institutional study
    Liselotte N Dyrbye
    Mayo Clinic, Department of Medicine, Rochester, Minnesota, USA
    Acad Med 85:94-102. 2010
    ..The authors assessed the severity of thoughts of dropping out and explored the relationship of such thoughts with burnout and other indicators of distress...
  61. doi request reprint Therapeutic exercise during outpatient radiation therapy for advanced cancer: Feasibility and impact on physical well-being
    Andrea L Cheville
    Departments of Physical Medicine and Rehabilitation, Mayo Clinic, Rochester, Minnesota, USA
    Am J Phys Med Rehabil 89:611-9. 2010
    ..To characterize the feasibility of delivering a structured physical therapy (PT) program as part of a multidisciplinary intervention to patients undergoing outpatient radiation therapy for advanced cancer...
  62. ncbi request reprint Painful metastases involving bone: feasibility of percutaneous CT- and US-guided radio-frequency ablation
    Matthew R Callstrom
    Department of Radiology, Mayo Clinic, 200 First St SW, E2, Rochester, MN 55905, USA
    Radiology 224:87-97. 2002
    ..To determine the safety and efficacy of radio-frequency (RF) ablation for pain reduction, quality of life improvement, and analgesics use reduction in patients with skeletal metastases...
  63. doi request reprint Association of resident fatigue and distress with perceived medical errors
    Colin P West
    Division of General Internal Medicine, Department of Medicine, Mayo Clinic, 200 First St, SW, Rochester, MN 55905, USA
    JAMA 302:1294-300. 2009
    ..Fatigue and distress have been separately shown to be associated with medical errors. The contribution of each factor when assessed simultaneously is unknown...
  64. pmc Evaluation of glutathione metabolic genes on outcomes in advanced non-small cell lung cancer patients after initial treatment with platinum-based chemotherapy: an NCCTG-97-24-51 based study
    Ping Yang
    College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Thorac Oncol 4:479-85. 2009
    ....
  65. pmc Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1
    Charles L Loprinzi
    Department of Oncology, Mayo Clinic, 200 First St, SW, Rochester, MN 55905, USA
    J Clin Oncol 29:1472-8. 2011
    ..The characteristics and natural history of the paclitaxel-acute pain syndrome (P-APS) and paclitaxel's more chronic neuropathy have not been well delineated...
  66. doi request reprint The learning environment and medical student burnout: a multicentre study
    Liselotte N Dyrbye
    Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Med Educ 43:274-82. 2009
    ..The authors conducted a comprehensive assessment of how learning environment, clinical rotation factors, workload, demographics and personal life events relate to student burnout...
  67. pmc The use of Valeriana officinalis (Valerian) in improving sleep in patients who are undergoing treatment for cancer: a phase III randomized, placebo-controlled, double-blind study (NCCTG Trial, N01C5)
    Debra L Barton
    Mayo Clinic Rochester, Rochester, MN 55905, USA
    J Support Oncol 9:24-31. 2011
    ..However, exploratory analyses revealed improvement in some secondary outcomes, such as fatigue. Further research with valerian exploring physiologic effects in oncology symptom management may be warranted...
  68. doi request reprint Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC
    Stephanie L Hines
    Mayo Clinic Jacksonville, Jacksonville, FL 32224, USA
    Breast Cancer Res Treat 117:603-9. 2009
    ..Patients in the upfront arm were slightly more likely to report limb edema, fatigue, fever, nausea and jaw osteonecrosis(1%). Upfront zoledronic acid prevents bone loss in postmenopausal women with BC starting letrozole after tamoxifen...
  69. pmc Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer
    Stephanie L Hines
    Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
    J Clin Oncol 27:1047-53. 2009
    ..Risedronate prevents bone loss in postmenopausal women. The purpose of this study was to determine whether risedronate prevents bone loss in premenopausal women undergoing chemotherapy for breast cancer...
  70. pmc Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy
    Stephanie L Hines
    Mayo Clinic Florida, Jacksonville, FL 32224, USA
    Breast 19:92-6. 2010
    ..Aromatase inhibitors further increase bone loss in these patients. This study evaluates whether zoledronic acid prevents the bone loss expected when these patients initiate letrozole...
  71. pmc Phase III, double-blind study of depot octreotide versus placebo in the prevention of acute diarrhea in patients receiving pelvic radiation therapy: results of North Central Cancer Treatment Group N00CA
    James A Martenson
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 26:5248-53. 2008
    ..To assess the effectiveness of depot octreotide for the prevention of diarrhea during pelvic radiation therapy...
  72. pmc The physician-patient relationship and quality of life: lessons from chronic lymphocytic leukemia
    Tait D Shanafelt
    Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, United States
    Leuk Res 33:263-70. 2009
    ..The effectiveness with which physicians help patients adjust to the physical, intellectual, and emotional challenges of CLL appears to impact patient QOL...
  73. pmc Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9
    Debra L Barton
    Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 28:3278-83. 2010
    ..Therefore, there is a continued need for rigorous evaluation to identify effective nonhormonal options for hot flash relief...
  74. ncbi request reprint Does megestrol acetate down-regulate interleukin-6 in patients with cancer-associated anorexia and weight loss? A North Central Cancer Treatment Group investigation
    Aminah Jatoi
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Support Care Cancer 10:71-5. 2002
    ..Our investigation provides no evidence that megestrol acetate down-regulates IL-6 in patients with cancer-associated anorexia and weight loss...
  75. ncbi request reprint Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7
    Charles L Loprinzi
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 24:1409-14. 2006
    ..This current trial compared a single intramuscular dose of medroxyprogesterone acetate (MPA), depot preparation, versus daily oral venlafaxine as treatment for hot flashes...
  76. ncbi request reprint Will improvement in quality of life (QOL) impact fatigue in patients receiving radiation therapy for advanced cancer?
    Paul Brown
    Department of Oncology, Mayo Clinic Rochester, Rochester, MN 55905, USA
    Am J Clin Oncol 29:52-8. 2006
    ..In this project, we examined the impact that participation in a randomized controlled trial of a multidisciplinary intervention designed to impact overall QOL had on fatigue for advanced cancer patients actively receiving treatment...
  77. ncbi request reprint Impacting quality of life for patients with advanced cancer with a structured multidisciplinary intervention: a randomized controlled trial
    Teresa A Rummans
    Department of Psychiatry and Psychology, Mayo Clinic Cancer Center, and Medical Social Services, Mayo Clinic, Rochester MN 55905, USA
    J Clin Oncol 24:635-42. 2006
    ....
  78. ncbi request reprint Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia
    Scott H Kaufmann
    Division of Hematology, Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN 55901, USA
    Clin Cancer Res 11:6641-9. 2005
    ..To assess the maximum tolerated dose, toxicities, pharmacokinetics, and antileukemic activity of topotecan and carboplatin in adults with recurrent or refractory acute leukemias...
  79. ncbi request reprint An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort
    Aminah Jatoi
    Mayo Clinic and Foundation, Rochester, MN 55905, USA
    J Clin Oncol 22:2469-76. 2004
    ..This study determined whether an EPA supplement-administered alone or with megestrol acetate (MA)-was more effective than MA...
  80. ncbi request reprint A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer
    Alex A Adjei
    Mayo Clinic and Foundation, Departments of Oncology and Medicine, Rochester, Minnesota 55905, USA
    Clin Cancer Res 9:2520-6. 2003
    ..This Phase I study was undertaken to define the toxicity, pharmacodynamics, and maximum tolerated dose of the combination of R115777, a farnesyl transferase inhibitor, with gemcitabine and cisplatin in patients with advanced solid tumors...
  81. ncbi request reprint Pilot evaluation of gabapentin for treating hot flashes
    L Loprinzi
    Division of Medical Oncology, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 77:1159-63. 2002
    ..To obtain pilot prospective data regarding the efficacy and tolerability of gabapentin for alleviating hot flashes...
  82. ncbi request reprint Genetic determinants of lung cancer short-term survival: the role of glutathione-related genes
    Ping Yang
    Department of Health Sciences Research, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Lung Cancer 35:221-9. 2002
    ..We tested the hypothesis that genes encoding glutathione enzymes may predict lung cancer short-term survival...
  83. ncbi request reprint A Phase I study of bizelesin (NSC 615291) in patients with advanced solid tumors
    Henry C Pitot
    Division of Medical Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Clin Cancer Res 8:712-7. 2002
    ..To evaluate the toxicities, characterize the pharmacokinetics, and determine the maximum-tolerated dose of bizelesin administered once every 4 weeks...
  84. ncbi request reprint Evaluation of the National Eye Institute visual function questionnaire in Graves' ophthalmopathy
    Elizabeth A Bradley
    Department of Ophthalmology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Ophthalmology 113:1450-4. 2006
    ..To determine the potential suitability of the 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25) for measuring health-related quality of life (HRQL) in patients with Graves' ophthalmopathy...
  85. ncbi request reprint Association of perceived medical errors with resident distress and empathy: a prospective longitudinal study
    Colin P West
    Division of General Internal Medicine, Department of Medicine, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    JAMA 296:1071-8. 2006
    ..Medical errors are associated with feelings of distress in physicians, but little is known about the magnitude and direction of these associations...
  86. ncbi request reprint The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients
    Ruben A Mesa
    Department of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 109:68-76. 2007
    ..Few objective data exist on the burden of fatigue and other constitutional symptoms in patients with myeloproliferative disorders (MPD)...
  87. ncbi request reprint Painful metastases involving bone: percutaneous image-guided cryoablation--prospective trial interim analysis
    Matthew R Callstrom
    Department of Diagnostic Radiology, Oncology, Biostatistics, and Anesthesiology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Radiology 241:572-80. 2006
    ....
  88. ncbi request reprint Quality of life of caregivers of patients with advanced-stage cancer
    Matthew M Clark
    Department of Psychiatry and Psychology, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA
    Am J Hosp Palliat Care 23:185-91. 2006
    ..Further investigation is warranted in this area, including interventions specifically designed and targeted to both reduce caregiver burden and to improve caregiver QOL...
  89. ncbi request reprint Phase III evaluation of fluoxetine for treatment of hot flashes
    Charles L Loprinzi
    Division of Medical Oncology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    J Clin Oncol 20:1578-83. 2002
    ..Based on anecdotal information regarding the efficacy of fluoxetine and other newer antidepressants for treating hot flashes, the present trial was developed...
  90. ncbi request reprint Neuropeptide Y, leptin, and cholecystokinin 8 in patients with advanced cancer and anorexia: a North Central Cancer Treatment Group exploratory investigation
    A Jatoi
    Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Cancer 92:629-33. 2001
    ..Anorexia is a noxious symptom, and over half of patients with advanced cancer experience it. Neuropeptide Y (NPY), leptin, and cholecystokinin 8 (CCK8) have been implicated...
  91. ncbi request reprint Aerosol granulocyte macrophage-colony stimulating factor: a low toxicity, lung-specific biological therapy in patients with lung metastases
    P M Anderson
    Department of Pediatrics, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Cancer Res 5:2316-23. 1999
    ..Aerosol delivery of GM-CSF is feasible, safe, and possibly effective. Aerosol cytokine delivery may achieve effective immunological activation against cancer in the lung and is worthy of further study...
  92. ncbi request reprint Quality of Life endpoints in prostate chemoprevention trials
    J A Sloan
    Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, Minnesota 55905, USA
    Urology 57:235-40. 2001
    ..As such, great care needs to be given to a priori determination of the QOL constructs that are most likely to change...
  93. ncbi request reprint A prospective study of the relationship between medical knowledge and professionalism among internal medicine residents
    Colin P West
    Division of General Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55095, USA
    Acad Med 82:587-92. 2007
    ..To explore residents' competency in medical knowledge and in empathy, one element of professionalism, and to evaluate the relationship between competencies in these domains...
  94. ncbi request reprint Efficacy and quality-of-life data are related in a phase II trial of oral chemotherapy in previously untreated patients with metastatic colorectal carcinoma
    Timothy J Hobday
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 20:4574-80. 2002
    ..To evaluate quality of life (QOL) and tumor response after administration of an oral chemotherapy regimen in patients with previously untreated metastatic colorectal cancer...
  95. ncbi request reprint A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma
    Aminah Jatoi
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer 97:1442-6. 2003
    ..This Phase II trial explored green tea's antineoplastic effects in patients with androgen independent prostate carcinoma...
  96. ncbi request reprint Comparison of nicotine patch alone versus nicotine nasal spray alone versus a combination for treating smokers: a minimal intervention, randomized multicenter trial in a nonspecialized setting
    Gary A Croghan
    Mayo Clinic and Mayo Foundation Rochester MN 55905, USA
    Nicotine Tob Res 5:181-7. 2003
    ..Combination nicotine nasal spray and nicotine patches were delivered safely in a nonspecialized outpatient clinical setting and enhanced short-term smoking abstinence rates, but these rates were not sustained at 6 months...
  97. ncbi request reprint Interpreting and reporting results based on patient-reported outcomes
    Dennis A Revicki
    Center for Health Outcomes Research, United BioSource Corporation, Bethesda, MD, USA
    Value Health 10:S116-24. 2007
    ..Clinical trial reports need to be comprehensive, clear, and sufficient to enable any reader to understand the methods, PRO measures, statistical analysis, and results...
  98. ncbi request reprint Patient assessment of bowel function during and after pelvic radiotherapy: results of a prospective phase III North Central Cancer Treatment Group clinical trial
    Michael G Haddock
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 25:1255-9. 2007
    ..To evaluate patient assessment of long-term effect of pelvic radiotherapy on bowel function...
  99. ncbi request reprint Assessing clinical significance in measuring oncology patient quality of life: introduction to the symposium, content overview, and definition of terms
    Jeff A Sloan
    Department of Health Sciences Research, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 77:367-70. 2002
    ..A secondary goal is to stimulate further discussion and research in the interpretation of QOL assessments...
  100. ncbi request reprint A pooled analysis of quality of life measures and adverse events data in north central cancer treatment group lung cancer clinical trials
    Mashele M Huschka
    Division of Biostatistics, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 109:787-95. 2007
    ....
  101. ncbi request reprint Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study
    Aminah Jatoi
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 20:567-73. 2002
    ..To determine whether dronabinol administered alone or with megestrol acetate was more, less, or equal in efficacy to single-agent megestrol acetate for palliating cancer-associated anorexia...